Moreover, the patients must undergo a minimum of three major classes of MM treatment lines, including an immunomodulating agent, a PI, and an anti-CD38 monoclonal antibody, or be classified as double refractory to a PI and an IMiD. Here, CD38 is linked to Miyoshi myopathy.